Peptonic Medical AB Said on Wednesday had completed a rights issue of 6 million Swedish crowns ($701,582.07) (before transaction costs equivalent to 10 pct of the total rights issue amount), to a selected group of new investors.
A total of 1,428,572 shares were issued at a subscription price of 4.20 crowns per share.
Proceeds from this rights issue will be used to start the preparations of the clinical phase 3 programme as well as to start preparing and conducting a pilot study on a new medical indication that is protected by patents proprietary to the Company.
The number of issued shares in the Company will increase by 1,428,572 to 20,602,984, corresponding to a share capital of 2,060,298.40 crowns as a result of this rights issue.
Source : reuters.com